Arunjyoti Bio Ventures Ltd (ABVL) Fair Value & Analysis
Industrials · IN · Market cap ₹939M
Strengths
Risks
Fair value as of: Aug 25, 2026
From 10 valuation models · updated today
Fair value updated Aug 25, 2026, revised from ₹0.4500 to ₹0.9900 (+120.0%) since Aug 16, 2026. Share price −5.5% over the past month.
Below-average quality, and trading another 406% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹1.53). The favourable scenario is already priced in.
- Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (₹0.4600 to ₹1.53). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 25, 2026.
How to read this chart
60‑month range ₹0.0554 – ₹20.18 · fair‑value band ₹0.4600 – ₹1.53 · the ₹5.01 price screens above the ₹0.9900 fair value. Dashed = 300-day average. As of Aug 25, 2026.
Analysis
Arunjyoti Bio Ventures Ltd (ABVL) currently trades at ₹5.01, while our model-based Fair Value estimate is ₹0.9900, implying the stock looks roughly 80.2% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Arunjyoti Bio Ventures Ltd generated revenue of ₹278M at a net margin of -16.3%. Revenue grew 37.0% year over year. It earns a return on equity of -14.9%. Net debt stands at ₹216M. Fundamentals as of Aug 25, 2026
Our scenario range runs from ₹0.4600 (bear case) to ₹1.53 (bull case); at ₹5.01, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 61% below its 52-week high, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -22% fair-value upside, at -80%, ABVL screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: Growth DCF (₹7.09) versus Asset-Based (₹1.03). Highest evidence: Growth DCF (80).
Notify me when ABVL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Arunjyothi Bio Ventures Limited engages packing services in India. It serves carbonated and non-carbonated water beverage application products. Arunjyothi Bio Ventures Limited was formerly known as Century 21st Portfolio Limited and changed its name to Arunjyothi Bio Ventures Limited in 2014.
Full company description
Arunjyothi Bio Ventures Limited engages packing services in India. It serves carbonated and non-carbonated water beverage application products. Arunjyothi Bio Ventures Limited was formerly known as Century 21st Portfolio Limited and changed its name to Arunjyothi Bio Ventures Limited in 2014. The company was incorporated in 1986 and is based in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Arunjyoti Bio Ventures Ltd reported revenue of ₹278M in FY2026 versus ₹29.7M in FY2022, a compound +74.8%/yr. Reported net income was −₹45.4M in FY2026.
ABVL screens 80% overvalued. Compare with Cintas Corporation →
Peer Group
Specialty Business Services · 255 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Business Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Specialty Business Services stocks, each showing price versus our Fair Value estimate (as of Aug 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Cintas Corporation CTAS | $199.52 | $95.19 | -52% |
| RELX PLC RELX | $34.55 | $32.24 | -7% |
| Thomson Reuters Corporation TRI | C$142.85 | C$70.40 | -51% |
| Copart, Inc CPRT | $28.99 | $28.59 | -1% |
| Global Payments Inc GPN | $88.53 | $68.98 | -22% |
| RB Global, Inc RBA | C$120.52 | C$49.14 | -59% |
| Brambles Limited BXB | A$19.47 | A$17.27 | -11% |
| UL Solutions Inc ULS | $76.68 | $33.62 | -56% |
| Wolters Kluwer N.V WKL | €69.78 | €101.27 | +45% |
| Aramark ARMK | $60.35 | $13.18 | -78% |
Compare Arunjyoti Bio Ventures Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Industrials stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Arunjyoti Bio Ventures Ltd (ABVL) overvalued or undervalued?
What is the fair value of ABVL?
What is the quality score of ABVL?
What is the revenue of Arunjyoti Bio Ventures Ltd (ABVL)?
What is the net profit margin of ABVL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Arunjyoti Bio Ventures Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.